Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Genmab A/S (GMAB) shares

Learn how to easily invest in Genmab A/S shares.

Genmab A/S is a biotechnology business based in the US. Genmab A/S stocks (GMAB.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $42.77 – a decrease of 6.16% over the previous week. Genmab A/S employs 1,136 staff and has a trailing 12-month revenue of around $7.9 billion.

How to buy shares in Genmab A/S

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GMAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Genmab A/S stock price (NASDAQ:GMAB)

Use our graph to track the performance of GMAB stocks over time.

Genmab A/S shares at a glance

Information last updated 2022-01-17.
Latest market close$33.50
52-week range$30.10 - $49.07
50-day moving average $39.46
200-day moving average $41.55
Wall St. target price$46.36
PE ratio 53.3075
Dividend yield N/A (0%)
Earnings per share (TTM) $0.67

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Genmab A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Genmab A/S price performance over time

Historical closes compared with the close of $33.5 from 2022-01-21

1 week (2022-01-14) -6.16%
1 month (2021-12-23) -15.60%
3 months (2021-10-22) -28.31%
6 months (2021-07-23) -25.31%
1 year (2021-01-22) -22.20%
2 years (2020-01-23) 45.78%
3 years (2019-01-23) 123.15%
5 years (2017-01-23) 91.984

Is Genmab A/S under- or over-valued?

Valuing Genmab A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Genmab A/S's P/E ratio

Genmab A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 53x. In other words, Genmab A/S shares trade at around 53x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Genmab A/S's PEG ratio

Genmab A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.6579. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Genmab A/S's EBITDA

Genmab A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.4 billion.

The EBITDA is a measure of a Genmab A/S's overall financial performance and is widely used to measure a its profitability.

Genmab A/S financials

Revenue TTM $7.9 billion
Operating margin TTM 39.43%
Gross profit TTM $10.1 billion
Return on assets TTM 8.57%
Return on equity TTM 14.45%
Profit margin 36.34%
Book value $32.55
Market capitalisation $23.4 billion

TTM: trailing 12 months

Genmab A/S share dividends

We're not expecting Genmab A/S to pay a dividend over the next 12 months.

Have Genmab A/S's shares ever split?

Genmab A/S's shares were split on a 5:1 basis on 30 April 2018. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab A/S shares which in turn could have impacted Genmab A/S's share price.

Genmab A/S share price volatility

Over the last 12 months, Genmab A/S's shares have ranged in value from as little as $30.1 up to $49.07. A popular way to gauge a stock's volatility is its "beta".

GMAB.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab A/S's is 0.6798. This would suggest that Genmab A/S's shares are less volatile than average (for this exchange).

Genmab A/S overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site